Inflammation and oxidative stress play key roles in atherosclerotic plaque instability, and plaque rupture/erosion and subsequent thrombus formation constitute the principal mechanisms of total vessel occlusion and acute ST-elevation myocardial infarction (STEMI). Plaque disruption triggers the formation of initial platelet aggregates that grow in association with an increase in fibrin formation, leading to persistent coronary flow obstruction and blood coagulation. The fibrin network may trap large numbers of erythrocytes and inflammatory cells to form an erythrocyte-rich thrombus. In fact, previous clinical studies have shown that not only platelet-rich white thrombi, but also erythrocyte-rich red thrombi can be visualized using angioscopy in patients with acute coronary syndrome. Recently, the development of thrombus aspiration and distal protection devices has significantly improved the clinical outcomes of percutaneous intervention in STEMI patients and has enabled the evaluation of antemortem coronary artery thrombi. This is important because previous autopsy studies were unable to differentiate coronary thrombi responsible for myocardial ischemia from postmortem clots. Using frozen samples of aspirated thrombi and specific monoclonal antibodies, we investigated the cellular components of thrombi (platelets, erythrocytes, fibrin and inflammatory cells, such as myeloperoxidase-positive cells) and pathologically evaluated the relationships between erythrocyterich thrombi and inflammation, oxidative stress and clinical outcomes in STEMI patients. Therefore, this review article focuses on the efficacy of thrombus aspiration therapy and the components of aspirated intracoronary thrombi in STEMI patients and presents the results of recent studies regarding the relationship between the composition of aspirated intracoronary thrombi and clinical outcomes. 
Introduction
Inflammation and increased oxidative stress play important roles in the pathogenesis of atherosclerosis and plaque instability [1] [2] [3] , and atherosclerotic plaque rupture or erosion and subsequent thrombus formation constitute the principal mechanisms of total vessel occlusion and acute ST-elevation myocardial infarction (STEMI) [4] [5] [6] [7] . Previous pathological analyses have revealed that coronary thrombi primarily consist of platelets, erythrocytes and fibrin and often contain atherosclerotic inflammatory cells [8] [9] [10] [11] [12] [13] [14] [15] . Numerous studies have focused on the platelet and/or fibrin component of coronary thrombi [16] [17] [18] , and tissue factor has also been reported to be involved in the pathogenesis of atherosclerosis by promoting thrombus forma--A Systematic Review -
Role of Tissue Factor and Microparticles in Thrombus Formation
In atherosclerotic plaques, macrophages and smooth muscle cells produce large amounts of tissue factor, a trigger of the coagulation system, and abundant tissue factor is expressed in advanced atherosclerotic lesions 16, 27, 28) . Therefore, plaque disruption leading to tissue factor exposure to flowing blood triggers coagulation activation and initiates platelet-fibrin thrombus formation. In fact, the plasma tissue factor levels and the expression/activity of tissue factor by circulating monocytes have been shown to be elevated in patients with ACS 29, 30) or metabolic syndrome 31) . These findings suggest that abundant tissue factor within plaque is the major factor responsible for the formation of large-size fibrin-rich thrombi and that local/systemic activation of monocytes increases the thrombogenic potential of the blood flow, thus leading to the onset of ACS 32) . Microparticles (MPs) are 0.1-1-μm membrane vesicles that are released into the extracellular space following cell activation or apoptosis 33) . Several cardiovascular risk factors, such as oxidative stress and elevated levels of lipoproteins and cytokines, increase the release of MPs from vascular/circulation cells 34, 35) , and a large number of studies have proposed that MPs may contribute to atherosclerotic plaque development and thrombus formation/progression [35] [36] [37] [38] . In fact, circulating MPs (primarily endothelial and leukocyte MPs), which contribute to the initiation of atherosclerosis due to endothelial dysfunction by decreasing nitric oxide synthesis, have been reported to be significantly higher in ACS patients 39) and are considered to be a primary source of the blood-borne tissue factor involved in thrombus propagation at the site of vascular injury 38, 40, 41) . In addition, human atherosclerotic plaques contain high levels of MPs, and a large number of human plaque MPs express CD40 ligand and harbor tissue factor, increasing their procoagulant activity 35) . Human plaque MPs are reported to be significantly prothrombogenic because they generate twice as much thrombin as circulating MPs in the same patient 42) . At the time of plaque disruption, locally released plaque MPs (particularly tissue factorpositive MPs), circulating tissue factor-bearing MPs and platelet-derived MPs contribute to the concentration of tissue factor activity at the thrombus edge, leading to fibrin-rich thrombus formation 35, 38, 40) . tion [19] [20] [21] [22] . However, little is so far known about the erythrocyte component of coronary thrombi because previous autopsy studies were unable to differentiate coronary thrombi responsible for STEMI from postmortem clots. Recently, the development of thrombectomy and distal protection devices has significantly improved myocardial perfusion and clinical outcomes and has enabled the evaluation of antemortem (true) coronary artery thrombi. In this review, we focus on the efficacy of thrombus aspiration therapy and the components of aspirated intracoronary thrombi in STEMI patients and present the results of our recent studies.
Mechanisms of Coronary Thrombus Formation
Coronary thrombi that develop either in plaque rupture or erosion sites are dynamic and evolve in stages [8] [9] [10] [11] [12] [13] [14] [15] . When the thin fibrous cap is disrupted, collagen and tissue factor become exposed to flowing blood, which triggers the accumulation and activation of platelets and converts fibrinogen to fibrin, thereby initiating thrombus formation. In the initial stage of thrombus formation, platelets aggregate within the lipid core, and the thrombus begins to protrude into the lumen. In some cases, spontaneous dissolution and plaque healing occur or stable mural thrombi are formed. Indeed, several studies have shown that asymptomatic plaque disruption and coronary thrombosis sometimes occur in nonculprit lesions in the coronary arteries in patients with coronary artery disease 23) or noncardiac death 24) . However, in other cases, platelet aggregation continues, and the vessel is partially occluded. In this stage, an antegrade intermittent flow is often present over the exposed thrombus and clumps of activated platelets may microembolize the distal vasculature. The thrombus grows in association with the formation of a fibrin network until the entire vessel is eventually occluded. Fibrin may accumulate over the plaque, stabilize the thrombus and entrap large numbers of erythrocytes and inflammatory cells, forming a red thrombus. The erythrocyterich thrombus in this final stage may propagate proximally and distally after the onset of STEMI. In fact, previous clinical studies have shown that not only platelet-rich white thrombi, but also erythrocyte-rich red thrombi can be directly visualized using angioscopy in patients with acute coronary syndrome (ACS) 25, 26) .
recently analyzed prospective data for 2,567 consecutive STEMI patients treated with p-PCI and reported that thrombectomy was associated with significant reductions in in-hospital mortality (OR 0.51, 95% CI 0.29-0.93, p = 0.027) and long-term mortality (OR 0.69, 95% CI 0.48-0.96, p = 0.028) during a mean follow-up of 9.9±3.8 months 72) . Based on these findings, if not anatomically contraindicated, adjunctive manual thrombectomy devices should be widely and routinely used in STEMI patients undergoing p-PCI.
Pathological Analysis of Aspirated Intracoronary Thrombi
The results of histopathological evaluations of aspirated intracoronary thrombi obtained from STEMI patients have recently been presented [73] [74] [75] [76] [77] . Rittersma et al. investigated 199 aspirated intracoronary thrombi obtained from STEMI patients within six hours of symptom onset and pathologically classified them into fresh thrombi (＜1 day old) composed of layered patterns of fibrin and intact platelets, erythrocytes and granulocytes and older thrombi with lytic (1 to 5 days) or organized (＞5 days) changes 73) . In that study, 50% of the thrombi were days or weeks old. Moreover, Nagata et al. evaluated 77 thrombi aspirated from STEMI patients within 24 hours of symptom onset and demonstrated that the dominant cell type of thrombi in the early phase of STEMI was platelets and that large thrombi in the right coronary artery contained more erythrocytes 74) . However, these studies were based on thrombi fixed in formalin, and the thrombus components (platelets, erythrocytes, fibrin and inflammatory cells) were not evaluated using immunohistochemical methods with specific antibodies. Our study was based on frozen thrombus samples because monoclonal antibodies against glycoprotein (GP) Ⅱb/Ⅲa and P-selectin only work well on frozen sections 78) . Using frozen samples of aspirated thrombi and these monoclonal antibodies, we evaluated the components of thrombi obtained from 178 STEMI patients 78) . In the erythrocyte-rich thrombi, the majority of the areas were stained positively for glycophorin-A (Fig. 1A, B) , while the GP Ⅱb/Ⅲa-and P-selectin-positive areas were small. In these thrombi, the erythrocyte-positive areas were the inverse of the GP Ⅱb/Ⅲa-and P-selectin-positive areas, and abundant myeloperoxidase (MPO)-positive neutrophils (Fig. 1C) and CD68-positive macrophages were found within the thrombi. In the thrombi, fibrin was also detected, and staining positivity for fibrin was present in the sites of platelets with GP Ⅱb/Ⅲa and P-selectin
Thrombus Aspiration/Distal Protection Therapy and Its Efficacy
The presence of an intracoronary thrombus at the culprit lesion site may increase the risk of distal embolization (DE), resulting in microvascular damage and left ventricular dysfunction during primary percutaneous coronary intervention (p-PCI) [43] [44] [45] [46] [47] . In this regard, the use of a mechanical device for thrombus removal or trapping to improve clinical outcomes after p-PCI is attractive, and the efficacy of these devices has been tested in many clinical trials. Although some data, especially those regarding the use of distal protection devices, have failed to show clinical benefits due in part to patient and device selection [48] [49] [50] [51] [52] [53] , many recent large-scale randomized trials have demonstrated significant improvements in myocardial perfusion 45, [54] [55] [56] [57] [58] [59] [60] [61] [62] [63] [64] [65] [66] [67] and the left ventricular function 64, 65) in addition to reduced mortality 68) ( 69) . In addition, Burzotta et 70) . With regard to long-term clinical outcomes, Burzotta et al. also performed a pooled analysis of 2,686 individual patients evaluated in 11 prospective randomized trials comparing standard PCI with or without thrombectomy to evaluate the impact of thrombectomy on long-term clinical outcomes. That analysis showed that thrombectomy use was associated with significantly lower all-cause mortality (log-rank p = 0.049) and reduced rates of major adverse cardiac events (log-rank p = 0.011) and death plus MI (log-rank p = 0.015) during a median follow-up of 365 days 71) . In addition, Noman et al. Ali et al. 49) (AIMI study) Beran et al.
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Vlaar et al. 24.9±23% (＜3 hours) to 9.1±6% (＞6 hours) (p = 0.07). Moreover, a multivariate analysis indicated that the ischemic time was the only independent predictor of thrombus composition. Similarly, Iwata et al. reported that the platelet content of intracoronary thrombi, as determined with immunostaining for CD42a, was negatively correlated with the time from the onset of chest pain (r = −0.683, p＜0.01) 80) . However, the "actual ischemic time" in clinical practice is defined as the time from the coronary event to the onset of reperfusion, which is not necessarily the same as the time from symptom onset. In fact, Rittersma et al. evaluated 199 aspirated thrombi obtained from 211 consecutive STEMI patients within six hours after the onset of chest pain and reported that the coronary thrombi were several days or weeks old in at least 50% of the patients with acute STEMI 73) . These results reflect the fact that aspirated thrombi may be older than expected based on the duration of the ischemic time and indicate that partial vessel occlusion leading to ACS frequently occurs days or weeks before positivity. In the platelet-rich thrombi, the erythrocyte-positive areas were small, and most thrombi were stained positively for GP Ⅱb/Ⅲa and P-selectin. In these platelet-rich thrombi, there were only a few MPO-positive neutrophils and macrophages 78) . Furthermore, fibrin was also detected, and staining positivity for fibrin was present in the platelet sites that stained positive for GPⅡb/Ⅲa and P-selectin.
Coronary Thrombus Components and the Ischemic Time
Recently, Silvain et al. analyzed 45 intracoronary thrombi obtained by aspiration from 288 consecutive STEMI patients using electron microscopy and clearly showed a relationship between the coronary thrombus components and the ischemic time 79) . That study demonstrated that the fibrin content increased in association with the ischemic time, ranging from 48.4± 21% (＜3 hours) up to 66.9±9% (＞6 hours) (p = 0.02), whereas the platelet content decreased from 83) . That study consisted of two substudies including 25 ACS patients and 22 sudden coronary death victims. The first substudy investigated the relationship between culprit lesion morphology assessed with optical coherence tomography (OCT) and the serum MPO levels in 25 ACS patients (12 STEMI patients and 13 non-STEMI patients) and found that the serum MPO levels were significantly higher in the patients with eroded plaques (n = 7) than in those with ruptured plaques (n = 18) [erosion vs. rupture: 2,500 ng/ml (range: 1,415-2,929) vs. 707 ng/ml (range 312-943), p = 0.001]. In the second substudy, the authors immunohistochemically analyzed the relationship between coronary plaque morphology and the density of MPO-positive cells within thrombi overlying plaques in 22 sudden coronary death victims. The results showed that the number of MPO-positive cells (neutrophils and some macrophages) within thrombi was significantly higher in the lesions with erosion (n = 11) than in the lesions with rupture (n = 11) [erosion vs. rupture: 1,584 cells/mm 2 (range: 1,088-2,135) vs. 579 cells/mm 2 (range: 442-760), p = 0.0012]. All of these previous studies performed postmortem analyses of coronary thrombi rather than antemortem assessments of culprit plaque morphology using imaging modalities, such as intravascular ultrasound (IVUS) or OCT, and pathological analyses of aspirated intracoronary thrombi in living patients were not performed. Our study used antemortem aspirated intracoronary thrombi and showed that erythrocyte-rich thrombi contain more MPO-positive cells; however, we did not fully assess plaque morphology using IVUS or OCT at the same time 78) . Therefore, further studies are needed to confirm the association between coronary thrombus components and plaque morphology in patients with acute STEMI.
Coronary Thrombus Components and Clinical Outcomes
Several recent studies have demonstrated associations between coronary thrombus characteristics and DE/myocardial perfusion 46, 47, 77, 78, 84) , restenosis 80) , the left ventricular (LV) function/remodeling 77, 78) and long-term mortality 75) (Table 2) .
Distal Embolization and Myocardial Perfusion
Plaque volume and composition, particularly the necrotic core volume, has been shown to be associated with DE in patients with STEMI 85, 86) . The presence symptom onset. In addition, our recent study including STEMI patients presenting within 12 hours of symptom onset revealed three types of aspirated coronary thrombi: 1) platelet-rich, low-erythrocyte thrombi, 2) platelet and erythrocyte-mixed thrombi and 3) erythrocyte-rich, low-platelet thrombi. These three types were observed despite a similar time from symptom onset to reperfusion among the three groups 78) . Moreover, many of the patients with erythrocyte-rich thrombi were smokers and had high plasma levels of oxidative stress markers (MPO and oxidized low-density lipoprotein) 78) . Another report demonstrated that circulating soluble CD40 ligand (sCD40L: an index of platelet activation) rather than the time to reperfusion, is the most important predictor of angiographic high-burden thrombus formation in the acute phase (onset ＜12 hours) of STEMI 81) . These findings suggest that thrombus components may be dependent on not only the ischemic time, but also multiple factors influencing inflammation, oxidative stress and blood viscosity.
Coronary Thrombus and Plaque Morphology
There are three reports related to coronary thrombus and plaque morphology. Sato et al. investigated the proportion of fibrin and platelets in thrombi of ruptured and eroded coronary atherosclerotic plaques obtained from patients who had died of acute MI within three days of onset and reported that fibrin was more abundant than platelets in the thrombi of ruptured plaques (74±19% vs. 35±20%, p＜0.01), whereas platelets tended to be more abundant than fibrin in the thrombi of eroded plaques (51±6% vs. 70±21%, p＜0.07) 16) . The second report was on the relationship between thrombus age (healing) and plaque morphology in sudden coronary death victims 82) . In that study, Kramer et al. immunohistopathologically evaluated 111 sudden death victims who had coronary lesions (ruptures, n = 65; erosions, n = 50) with thrombi and determined the relationship between plaque morphology and thrombus healing classified as early (＜1 day) or late characterized in phases of lytic (1 to 3 days), infiltrating (4 to 7 days) or healing (＞7 days). The results showed that latestage thrombi were present in 79 (69%) of the 115 culprit plaques and that the majority of early thrombi (＜1 day) and lytic thrombi (1 to 3 days) were present in plaque ruptures as compared with erosions (46% vs. 12%, p＜0.0001), whereas the majority of thrombi in erosions were infiltrating (4 to 7 days) or healing (＞7 days) (46% vs. 9%, p＜0.001). Moreover, women more frequently had erosions with a greater dial reperfusion, as indicated by an incomplete STR (＜70%) and lower MBG (≤ 1), are frequently observed in patients with erythrocyte-rich thrombi (STR, p = 0.056; MBG, p＜0.01) 78) . Furthermore, Arakawa et al. demonstrated that a high neutrophil density in an aspirated thrombus (＞100 neutrophils/0.025 mm 2 thrombus) is associated with impaired coronary microcirculation, as assessed according to an MBG ≤1 and STR ＜50% 77) . These findings suggest that not only the thrombus size (burden), but also the thrombus components (erythrocytes and MPO-positive neutrophils) are associated with myocardial reperfusion in STEMI patients.
Restenosis
Iwata et al. analyzed 108 aspirated thrombi obtained from acute (＜24 hours) or recent (24-72 of intracoronary thrombi at the lesion site has also been shown to increase the risk of DE 44, 46, 47) . 47) . Moreover, we recently demonstrated that the erythrocyte component of intracoronary thrombi, as assessed with immunohistochemical staining of glycophorin-A (a protein specific to erythrocyte membranes), is an independent predictor of DE based on angiography in patients with STEMI 84) . In addition, our study also showed that signs of impaired myocar- Arakawa et al.
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Yunoki et al. Table 1. tor-positive MPs, local and systemic activation of inflammatory cells and various cardiovascular risk factors and immune-inflammatory/oxidative stressrelated factors influencing blood/erythrocyte properties may play important roles. At the time of plaque disruption, locally released tissue factor-positive and leukocyte-derived MPs play an important role in fibrin-rich thrombus formation [35] [36] [37] [38] [39] [40] [41] [42] . Moreover, activated inflammatory cells, such as neutrophils, macrophages and eosinophils, contribute to the growth of a thrombus 17, 89, 90) . Our study also demonstrated that erythrocyte-rich thrombi often contain more inflammatory cells, such as MPO-positive neutrophils, thus leading to increased plasma MPO levels, which reflects a high thrombus burden 78, 84) . These results suggest that local accumulation of activated inflammatory cells and a systemic inflammatory status contribute to thrombus growth, which is understandable when considering the mechanisms of thrombus formation and growth, as previously reported [8] [9] [10] [11] [12] [13] [14] [15] . Moreover, MPO itself and MPO-derived reactive oxygen species have been shown to increase the expression of tissue factor, leading to a thrombotic state 91) , and influence erythrocyte deformation and aggregation, leading to membrane generation, rouleau formation and higher blood viscosity [92] [93] [94] [95] [96] [97] . In addition, other cardiovascular risk factors (cigarette smoking, hyperglycemia) [98] [99] [100] [101] [102] [103] [104] [105] and immune-inflammatory/oxidative stress-related factors (C-reactive protein, CD40 ligand, fibrinogen and D-dimer, lipoprotein (a)) 81, [106] [107] [108] [109] [110] [111] [112] [113] [114] [115] [116] [117] [118] have been reported to influence the platelet-fibrin clot structure and blood viscosity/erythrocyte aggregation. These findings are of considerable interest, since they suggest that some factors influencing blood thrombogenicity/ viscosity and erythrocyte properties (deformability and/or aggregability) may play important roles in the evolution of erythrocyte-rich large thrombi. Schemas of the possible mechanisms of thrombus growth and the evolution of erythrocyte-rich thrombi are presented in Fig. 2 .
Conclusions
Thrombus aspiration in ACS patients has provided important histopathological information regarding thrombus composition, which may contribute to furthering our understanding of the pathophysiology of ACS. In studies based on the examination of thrombus specimens, sampling bias must be considered; nevertheless, evaluating the thrombus burden or components using both coronary angiography and intravascular imaging modalities, such as IVUS, angioscopy or OCT, may contribute to risk stratificahours) STEMI patients and reported that the presence of CD34-positive primitive cells in intracoronary thrombi positively correlated with restenosis on follow-up CAG (r = 0.76, p = 0.01) 80) .
LV Function and Remodeling
Ours and other studies have reported a relationship between the thrombus components and the LV function/remodeling. Arakawa et al. demonstrated that the LV ejection fraction (LVFE) at six months after MI was significantly lower in a group of patients with a high neutrophil density in the aspirated thrombus (＞100 neutrophils/0.025 mm 2 thrombus) than in a group with a low neutrophil density (42.4±1.4% vs. 47.1±1.5%, p＜0.05) 77) . In contrast, we showed that the LVFE on admission and at six months after STEMI are not significantly different among patients with platelet-rich, mixed and erythrocyte-rich thrombi; however, the progression of LV remodeling is frequently observed in patients with erythrocyterich thrombi (p＜0.01) 78) .
Long-Term Mortality
Recently, Kramer et al. showed that the presence of older thrombi is an independent predictor of longterm mortality in patients with STEMI treated with thrombus aspiration 75) . In that study, they classified the thrombi aspirated from 1,315 STEMI patients into fresh thrombi (＜1 day old) or older thrombi with lytic (1 to 5 days) or organized (＞5 days) changes immunohistochemically and showed that all-cause mortality was two-fold higher in the patients with older thrombi than in the patients with fresh thrombi at four years of follow-up (hazard ratio 1.82, 95% CI 1.17-2.85, p = 0.008).
Possible Mechanisms of Thrombus Growth
In the initial phase, the activation of platelets and the coagulation system plays an important role in thrombus formation and growth. Under conditions of a rapid flow in atherosclerotic arteries, von Willebrand factor has been shown to play an important role in platelet aggregation/adhesion and fibrin-rich thrombus formation 17, 87, 88) . Moreover, abundant tissue factor expressed in plaque and the vascular wall may also play a crucial role in the activation of the coagulation cascade and the formation of platelet-fibrin thrombi at the time of plaque disruption 16-22, 27, 28) . In the progressive phase of thrombus growth, both fibrin accumulation and platelet-fibrin stabilization and blood thrombogenicity/viscosity and erythrocyte properties are important; therefore, tissue fac-
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None declared. tion regarding thrombus features in order to determine whether the thrombus should be aspirated or a distal protection device should be used during p-PCI. Furthermore, future studies using a combination of pathological assessment and cardiovascular imaging should be conducted to confirm the association between thrombus characteristics and underlying plaque morphology in STEMI patients. 
